TransCode Therapeutics, Inc.
RNAZ · NASDAQ
Bulios Fair Price
$2.53
43.7% upside
Current Price
$1.76
According to Bulios Fair Price, RNAZ is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
TransCode Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutic products based on RNA. The company employs advanced technologies to modify and optimize RNA in order to create drugs for various diseases. Their research centers on utilizing RNA therapy to influence gene expression and provide novel approaches to treating various health conditions. TransCode Therapeutics aims to bring innovative treatment options and contribute to advancements in the field of biotechnology and therapeutic strategies. Investors interested in advancements in biotechnology and RNA therapy might see potential in TransCode Therapeutics, Inc. shares for innovation and growth in this field.
Sector
Healthcare
Industry
Biotechnology
CEO
Philippe Calais
Employees
12
Headquarters
Boston
Upcoming events
Earnings
Upcoming earnings report